Patients with knee osteoarthritis increasingly arrive at consultations having already bought a red light therapy device, or having already decided to. That changes the nature of the conversation. Rather than deciding whether to introduce a modality, the clinician is being asked to comment on one that is already in the patient’s living room, and to say whether the money was well spent.
An honest answer takes some care to construct, and it is worth resisting the temptation to default to either dismissal or enthusiasm. Photobiomodulation has a plausible biological mechanism, a large and inconsistent trial literature, and at least one national guideline body that has recommended against it.
It helps to know what patients are actually comparing when they shop. Consumer roundups of devices for knee recovery compiled by the Cybernews team catalogue the wavelength, irradiance, and treatment-time specifications that distinguish one unit from another, and those are the parameters that determine whether a home device delivers anything resembling a trial dose. The value of the Cybernews health-tech reviews in a clinical conversation is not as an endorsement of the modality but as a specification reference, since manufacturers frequently omit or obscure exactly the numbers a clinician would want to see.
What the mechanism actually claims
Photobiomodulation therapy, still often called low-level laser therapy in older literature, applies red or near-infrared light from a laser or LED source. The proposed mechanism is absorption by mitochondrial cytochrome c oxidase, with downstream effects on ATP production and on inflammatory signalling within the joint.
This is a coherent pathway with reasonable preclinical support. It is not, on its own, evidence of clinical benefit, and it is worth being careful that a tidy biochemical story does not end up doing work that the trial data has not done.
Where the evidence actually sits
| Source | Position relevant to light therapy in knee OA |
| ACR / Arthritis Foundation guideline (2019) | Emphasises multimodal management. Exercise and weight loss carry the strong recommendations. TENS was moved to strongly against on high-quality negative evidence |
| RACGP Australian guideline (2018) | Conditional recommendation against low-level laser therapy |
| WALT dosage recommendations | Wavelengths of 780 to 860 nm and 904 nm for musculoskeletal indications |
| Recent double-blind RCT (790 nm, 4 J per point, nine points, WALT-compliant) | Significant pain reduction versus both sham and no-treatment control |
| Network meta-analysis (2024) | Laser therapy combined with exercise therapy outperformed sham; wavelength selection appears to influence outcome |
Those rows do not agree with each other, and patients deserve to hear that rather than a manufactured consensus. A published narrative review of the Australian guideline pointed out that the recommendation against laser therapy rested on eight randomised trials, the most recent of which dated from 2012, while seventeen further trials had appeared since. Guidelines are snapshots, and this one was taken with an old lens. That said, the trial literature that has accumulated is itself heterogeneous, effect sizes vary considerably between studies, and blinding a sham light device convincingly is genuinely difficult. Neither confident endorsement nor confident dismissal is defensible from where the evidence currently stands.
What to say to a patient who already owns a device
The single most important message is that the exercise programme continues. Every meta-analysis showing benefit for photobiomodulation in knee OA examined it as an adjunct to exercise therapy, never as a substitute. A patient who quietly replaces their strengthening programme with a light panel has traded an intervention with robust evidence for one with contested evidence, which is a straightforwardly bad trade. This is the point at which it is worth revisiting the fundamentals of conservative management, and clinicalgate’s own overview of physical therapy treatments for knee osteoarthritis is a reasonable refresher to point trainees toward.
Beyond that, two specifics are worth checking with the patient. The first is wavelength: if the device does not operate in the ranges the World Association for Photobiomodulation Therapy specifies for musculoskeletal conditions, it is not delivering what the trials delivered, whatever the packaging says. The second is dose delivery. Trials apply a defined energy at multiple discrete points around the joint, typically several joules per point across eight or nine points. A panel held loosely in the vicinity of a knee for ten minutes is not the same intervention, even if the wavelength is right.
Adverse events across the photobiomodulation literature are rare and generally minor. That safety profile is the strongest practical argument for a permissive stance. A patient who wants to use a device alongside a properly supervised exercise programme is unlikely to come to harm, and the consultation is better spent on adherence to the exercise than on litigating the light.
Framing the answer honestly
Telling a patient this is proven overstates the case. Telling them it is worthless overstates it in the other direction, and both positions become awkward when the patient reads the next systematic review.
The defensible summary for most patients is that light therapy may add modest pain relief on top of an exercise programme, that device specifications matter a great deal and most consumers never check them, and that if a patient has to choose where to spend limited money, supervised physiotherapy has the better evidence behind it. That answer is less satisfying than a clean yes or no, but it is the one the current literature actually supports, and patients generally respond well to being told where the uncertainty lies rather than being handed false confidence.
